- Home
- DOCU vs RDY Comparison
DOCU vs RDY Comparison
Compare DOCU & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCU
- RDY
- Stock Information
- Founded
- DOCU 2003
- RDY 1984
- Country
- DOCU United States
- RDY India
- Employees
- DOCU N/A
- RDY N/A
- Industry
- DOCU EDP Services
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- DOCU Technology
- RDY Health Care
- Exchange
- DOCU Nasdaq
- RDY Nasdaq
- Market Cap
- DOCU 14.4B
- RDY 13.2B
- IPO Year
- DOCU 2018
- RDY N/A
- Fundamental
- Price
- DOCU $90.42
- RDY $15.41
- Analyst Decision
- DOCU Hold
- RDY Buy
- Analyst Count
- DOCU 16
- RDY 1
- Target Price
- DOCU $89.38
- RDY $17.00
- AVG Volume (30 Days)
- DOCU 3.1M
- RDY 1.6M
- Earning Date
- DOCU 03-06-2025
- RDY 01-28-2025
- Dividend Yield
- DOCU N/A
- RDY 6.21%
- EPS Growth
- DOCU 1852.18
- RDY 4.63
- EPS
- DOCU 4.82
- RDY 0.76
- Revenue
- DOCU $2,912,873,000.00
- RDY $3,579,112,656.00
- Revenue This Year
- DOCU $9.38
- RDY $16.39
- Revenue Next Year
- DOCU $6.42
- RDY $8.74
- P/E Ratio
- DOCU $18.77
- RDY $20.57
- Revenue Growth
- DOCU 7.52
- RDY 12.37
- 52 Week Low
- DOCU $48.70
- RDY $13.43
- 52 Week High
- DOCU $107.86
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- DOCU 50.69
- RDY 54.21
- Support Level
- DOCU $87.08
- RDY $15.41
- Resistance Level
- DOCU $93.44
- RDY $15.84
- Average True Range (ATR)
- DOCU 2.84
- RDY 0.21
- MACD
- DOCU -1.15
- RDY 0.01
- Stochastic Oscillator
- DOCU 36.15
- RDY 35.71
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in May 2018.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.